Data edition of
Residue An evidence-graded reference for peptide science

Bremelanotide research

What PubMed holds on Bremelanotide, sorted by study design: the papers this site relies on, every clinical-trial publication PubMed tags, and the newest additions.

PubMed records
113
Trial publications
1614 randomized
Reviews
57
Human-subject tagged
83
Animal-only
7
  • Clinical-trial publications 16
  • Reviews 57
  • Animal-only studies 7
  • Other (in vitro, chemistry, commentary, unindexed) 33
Figure 1. Composition of the Bremelanotide literature by PubMed publication type and MeSH tags. Categories come from separate PubMed filters and can overlap; “animal-only” means tagged Animals and not Humans. Query: (bremelanotide[tiab] OR PT-141[tiab]).
0714 2003: 2 records 2003 2004: 7 records 2005: 4 records 2005 2006: 5 records 2007: 7 records 2008: 7 records 2009: 0 records 2010: 0 records 2010 2011: 1 records 2012: 2 records 2013: 0 records 2014: 2 records 2015: 2 records 2015 2016: 2 records 2017: 5 records 2018: 4 records 2019: 6 records 2020: 7 records 2020 2021: 10 records 2022: 14 records 2023: 8 records 2024: 8 records 2025: 13 records 2025 2026: 11 records (year to date) 2026
Figure 2. PubMed records per publication year matching (bremelanotide[tiab] OR PT-141[tiab]) — 113 in total; peak 14 in 2022. The 2026 bar is year-to-date (hatched). Volume of literature is not evidence of efficacy. Run this query on PubMed.

Studies this site relies on

Ordered by strength of design. Conclusions are quoted verbatim from each abstract as indexed by PubMed; read the full paper before relying on any of them.

  1. Phase 3 trial J Womens Health (Larchmt) · 2022 PMID 35147466

    Safety Profile of Bremelanotide Across the Clinical Development Program

    Clayton AH, Kingsberg SA, Portman D, et al.

    Although not deemed clinically important, bremelanotide should be used with caution in patients at risk of cardiovascular disease, and blood pressure should be well controlled during treatment. Clinical Trial Registration number: NCT02333071 [Study 301] and NCT02338960 [Study 302].

  2. Phase 3 trial Obstet Gynecol · 2019 PMID 31599840

    Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

    Kingsberg SA, Clayton AH, Portman D, et al.

    Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with hypoactive sexual desire disorder. The safety profile was favorable. Most treatment-emergent adverse events were related to tolerability and the majority were mild or moderate in intensity.

  3. Phase 2 trial J Sex Med · 2019 PMID 31277966

    Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide

    Althof S, Derogatis LR, Greenberg S, et al.

    Bremelanotide was safe and well tolerated and demonstrated significant improvement in efficacy vs placebo in the phase 2b trial. The multiple responder analyses offer a valuable approach for determining clinically important effects of bremelanotide for HSDD and FSAD. Althof S, Derogatis LR, Greenberg S, et al. Responder Analyses from a …

  4. Primary study Diabetes Obes Metab · 2022 PMID 35170192

    Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials

    Spana C, Jordan R, Fischkoff S

    Agonist activity at the MC4R may aid in reducing caloric intake and weight loss in obese women.

  5. Primary study Obstet Gynecol · 2019 PMID 31599847

    Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder

    Simon JA, Kingsberg SA, Portman D, et al.

    During the 52-week open-label extension of RECONNECT, no new safety signals were observed, and premenopausal women treated with bremelanotide exhibited sustained improvements in hypoactive sexual desire disorder symptoms.

  6. Review J Sex Res · 2024 PMID 36809187

    Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder

    Spielmans GI, Ellefson EM

    Several other continuous and categorical outcomes generated modest apparent benefits, though nearly all of these outcomes were likely derived post-hoc. Across RECONNECT trial data from two prior publications and the current study, bremelanotide's benefits are statistically modest and limited to outcomes for which scant evidence of …

  7. Review Drugs · 2019 PMID 31429064

    Bremelanotide: First Approval

    Dhillon S, Keam SJ

    Bremelanotide is a synthetic peptide analogue of the neuropeptide hormone alpha melanocyte-stimulating hormone (α-MSH) with high affinity for the melanocortin type 4 receptor (thought to be important for sexual function), giving it the potential to modulate brain pathways involved in sexual response. This article summarizes the milestones …

Clinical-trial publications in PubMed

16 records carry PubMed’s clinical-trial publication type. Tagging is done by NLM indexers and occasionally includes secondary analyses.

Clinical-trial publications on Bremelanotide
YearTitleJournalDesign
2022Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of BremelanotideJ Womens Health (Larchmt)Randomized trial
2022Safety Profile of Bremelanotide Across the Clinical Development ProgramJ Womens Health (Larchmt)Phase 3 trial
2021The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study ResultsJ Womens Health (Larchmt)Randomized trial
2019Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsObstet GynecolPhase 3 trial
2019Responder Analyses from a Phase 2b Dose-Ranging Study of BremelanotideJ Sex MedPhase 2 trial
2017Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotideJ HypertensRandomized trial
2017Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female ParticipantsClin TherPhase 1 trial
2016Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trialWomens Health (Lond)Randomized trial
2008RETRACTED: Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized studyJ Sex MedRandomized trial
2008Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled studyJ UrolRandomized trial
2006An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonistJ Sex MedRandomized trial
2005Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile responseUrologyRandomized trial
2004Gateways to clinical trialsMethods Find Exp Clin PharmacolClinical trial
2004Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to ViagraInt J Impot ResPhase 2 trial
2004Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunctionInt J Impot ResPhase 1 trial
2003PT-141: a melanocortin agonist for the treatment of sexual dysfunctionAnn N Y Acad SciClinical trial

Newest records

The most recent PubMed additions for this query at the data-edition date, regardless of design.

← Back to the Bremelanotide monograph A